Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Ayisha Sharma

News Reporter

Cogent Biosciences said it’s working on an FDA submission for its systemic mastocytosis (SM) drug after breezing through a Phase 2 trial in an indolent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases